Interview: Ray O'Neill, Managing Director, ESS Ltd
Mr. O’Neill, you have been managing director of this company for 17 years. How have you evolved the business over that period? ESS was founded in 1991, and I joined…
Address: Novo Nordisk Ireland, 2nd Floor, 2 Hume St. Dublin 2,Ireland
Tel: 1850 665665
Web: http://www.novonordisk.ie/documents/home_page/document/index.asp
General information:
Irish office: 3/4 Upper Pembroke Street, Dublin 2
Global headquarters: Bagsværd, Denmark
Irish workforce: 24 employees
Global workforce: More than 31,300 employees
International production facilities in seven countries
Product areas
Diabetes care
Hormone replacement therapy (HRT)
Haemostasis management
Growth hormone therapy.
Clinical research:
Before any medicine is available for doctors to prescribe, it must be granted a license by the government. Therefore, all medicines have to be tested in appropriate patients to ensure that they reach the standards of safety and efficacy required by governmental agencies around the world. This is achieved by conducting clinical trials in which patients freely volunteer to try new medicines so that relevant data can be obtained. All clinical trials must conform to globally accepted scientific and ethical standards before they can proceed.
Novo Nordisk is committed to ensuring that all its products meet the highest quality standards and are rigorously tested by performing clinical trials in collaboration with doctors and nurses around the world, including sites in Ireland.
Novo Nordisk way:
In 1923, our Danish founders began a journey to change diabetes.
Today, we are thousands of employees across the world with the passion, the skills and the commitment to continue this journey to prevent, treat and ultimately cure diabetes.
Our ambition is to strengthen our leadership in diabetes. Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world. We aspire to change possibilities in haemophilia and other serious chronic conditions where we can make a difference. Growing our business and delivering competitive financial results is what allows us to help patients live better lives, offer an attractive return to our shareholders and contribute to our communities.
We never compromise on quality and business ethics
Our business philosophy is one of balancing financial, social and environmental considerations – we call it ‘The Triple Bottom Line’
We are open and honest, ambitious and accountable, and treat everyone with respect
We offer opportunities for our people to realise their potential.
Every day, we must make difficult choices, always keeping in mind, what is best for patients, our employees and our shareholders in the long run.
It’s the Novo Nordisk Way.
Haemophilia and Eating Disorders.
Diabetes Care.
Hormone Replacement Therapy.
Mr. O’Neill, you have been managing director of this company for 17 years. How have you evolved the business over that period? ESS was founded in 1991, and I joined…
Mr. O’Neill, you have been managing director of this company for 17 years. How have you evolved the business over that period? ESS was founded in 1991, and I joined…
Mr. Moore, can you please introduce our readers to yourself and to SteriPack? SteriPack was founded in Clara, Ireland, in 1994. When I joined the organization 18 years ago, we…
Can you please introduce our readers to Deloitte Ireland and the firm’s life science practice? Brendan Jennings (BJ): Deloitte’s presence in Ireland dates back over one hundred years. We currently…
Can you please introduce yourself and Arthur Cox’s life science practice to our readers? I am a partner within the technology and life sciences group at Arthur Cox, and head…
Mr. Cooke, you joined Alkermes after the company acquired the Elan Drug Technologies (EDT) unit in 2011—a unit you headed for four years. Can you please begin by introducing yourself…
Mr. Somers, can you please introduce us to the Helsinn Group and its unique in-licensing model? Helsinn is a Swiss-based, private company owned by the Braglia family. The Braglias have…
Mylan embarked upon its first major international expansion program in 2007, after the acquisition of Merck KGaA’s generic medicines business. How has the organization subsequently evolved in the UK/Ireland market…
Mr. Keogh, you founded Millmount Healthcare in 1999. What was the vision behind the company? Prior to founding Millmount, I spent ten years in pharmaceutical manufacturing and contract packaging in…
Can you please introduce us to Dalkia? Pat Gilroy: Dalkia is a multinational company that operates in over 40 countries throughout the world and turns over 8Bn EUR annually. We…
Mr. Garrahy, can you please begin by introducing yourself and this production facility to our readers? I joined Rottapharm in 1998, when the organization decided to establish its Dublin production…
Mr. Moran, can you please begin with a brief introduction to Pharmachemical Ireland, its mission, and how it works to achieve its goals? Pharmachemical Ireland (PCI) is an industry…
See our Cookie Privacy Policy Here